Lilly Q2 revenue $15.56B (+38% YoY), EPS $6.29 (+92%), raises FY guidance

ELI LILLY & Co

2025-Q2 EPS reported $9.35 revenue$28,286,200,000

Q2 revenue $15.56B, up 38% YoY, driven by volume growth from Zepbound and Mounjaro.
Reported EPS $6.29, up 92%; non-GAAP EPS $6.31, up 61%, both inclusive of $0.14 IPR&D charges.
Full-year revenue guidance raised $1.5B to $60-62B; reported EPS guided $20.85-22.10; non-GAAP EPS $21.75-23.00.
Pipeline progress: positive results for orforglipron in obesity, Mounjaro SURPASS CVOT in T2D and heart disease, and Jaypirca vs Imbruvica in CLL/SLL.
Completed acquisitions of SiteOne Therapeutics and Verve Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.